Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Arcellx

Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline

Gilead Sciences (NASDAQ:GILD) Chief Commercial Officer and Head of Corporate Affairs Johanna Mercier said the company is leaning on its HIV business while continuing to build out oncology and inflammation through recent acquisitions and pipeline development. Speaking at the Bank of America Healthca

MarketBeat

Rutgers graduation speaker canceled for pro-Palestinian posts says decision sends ‘dangerous’ message

Rami Elghandour tells Guardian in exclusive interview his speech was cancelled due to students’ complaints

The Guardian - US

Why Is Arcellx Stock Surging Today?

Arcellx Inc. (NASDAQ:ACLX) shared new data on Saturday from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel) for relapsed or refractory multiple myeloma (RRMM).

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

In-Depth Examination Of 14 Analyst Recommendations For Arcellx

In the last three months, 14 analysts have published ratings on Arcellx (NASDAQ:ACLX), offering a diverse range of perspectives from bullish to bearish.

Benzinga

14 Analysts Have This To Say About Arcellx

In the latest quarter, 14 analysts provided ratings for Arcellx (NASDAQ:ACLX), showcasing a mix of bullish and bearish perspectives.

Benzinga

2 Potential Stocks to Buy From Barchart’s ‘Death Cross’ Indicator

While a security’s short-term moving average dipping below its long-term average warrants caution, this dynamic may also be a contrarian indicator.

Barchart

GILD, BIIB, and KRTX: Biotech Buy, Hold, or Sell?

Rising healthcare needs, significant investments in R&D, robust drug pipeline, and use of advanced technology are some factors driving the biotech industry’s growth. Amid this favorable backdrop, let’s evaluate Gilead (GILD), Biogen (BIIB) and Karuna Therapeutics (KRTX) to determine the best investment action. Read more.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022

Upgrades

Benzinga

More Than $6 Million Bet On JELD-WEN Holding? 3 Stocks Insiders are Buying

Although the US stocks closed higher on Thursday, there were a few notable insider trades.

Benzinga

Expert Ratings for Arcellx

Analysts have provided the following ratings for Arcellx (NASDAQ:ACLX) within the last quarter:

Benzinga

$Arcellx Doses First Patient in Phase 1 study of ACLX-001 in Relapsed or Refractory Multiple Myeloma$

Arcellx Doses First Patient in Phase 1 study of ACLX-001 in Relapsed or Refractory Multiple Myeloma

Arcellx, Inc. (NASDAQ: ACLX) announced that the first patient has been dosed in its open-label, multi centre phase 1 clinical study of ACLX-001 for patients with Relapsed or Refractory Multiple Myeloma (r/r MM).

Benzinga

BofA Initiates Arcellx With Buy On Its Novel Therapy Approach

Arcellx (NASDAQ: ACLX) is advancing into pivotal testing (by year-end 2022) of its B-cell maturation antigen (BCMA) directed combination antiretroviral therapy (CART), known as ddBCMA, for relapsed refractory multiple myeloma, according to BofA Securities.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022

Upgrades

Benzinga

CAR-T Player Arcellx Raises $123M Via Initial Public Offering, Opens Trading At $19

CAR-T company Arcellx Inc (NASDAQ: ACLX) priced its IPO at

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

People

Dipanjan BanchurSince

722 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Advanced Micro Devices

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.